Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

US seeking price cuts for Medicare drugs

White House proposes allowing Medicare Part D to haggle with pharma companies for discounts

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

Gathering pace: adaptive pathways

EMA looks at how the model could work in practice and picks first drugs for its pilot project

Searching for junk

The pharma industry might be focusing on the wrong acquisitions

- PMLiVE

Extension for head of Germany’s VFA

Birgit Fischer to remain as chief executive of pharma trade body until 2019          

- PMLiVE

VCCP Health and Havas Life Medicom tie for first at PM Society Awards

Eachagency picked up three Gold trophies at annual ceremony in London

UK flag

No further price cut for non-PPRS drugs in UK

But industry concerned over long-term plan for statutory medicines on the NHS

- PMLiVE

Senior changes at Merck KGaA

New head of controlling for its healthcare business

- PMLiVE

Valeant lead bidder for troubled Dendreon

Willing to pay $296m for company behind prostate cancer vaccine Provenge

- PMLiVE

ICON to open global innovation hub in Ireland

Will create 200 new jobs

Eli Lilly HQ

Lilly eyes pivotal trials for pain drug tanezumab in 2015

Drug was placed under clinical hold by FDA in 2010

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links